All sponsors

Merck Sharp & Dohme LLC $MRK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS193
PHASE 3 / 2-3107
RECRUITING100
READOUTS ≤12 MONTHS35
READOUT SLIPPED >6 MO31%

Delay Index: of 144 active trials registered more than a year ago, 45 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Merck Sharp & Dohme LLC on the live radar map → 📅 $MRK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
pembrolizumab
NCT02362594
P3Active, not recruitingMelanoma10192018-01-08 (-4 mo)
Pembrolizumab
NCT03553836
P3Active, not recruitingMelanoma9762021-06-21 (-16 mo)
Pembrolizumab
NCT03425643
P3Active, not recruitingNon-small Cell Lung Cancer7972023-07-10 (-6 mo)
Belzutifan
NCT04195750
P3Active, not recruitingCarcinoma, Renal Cell7552024-04-15 (-17 mo)
Pembrolizumab/Vibostolimab Co-Formulation
NCT05224141
P3Active, not recruitingSmall Cell Lung Carcinoma4602024-06-04 (-11 mo)
Pembrolizumab Formulated with Berahyaluronidase Alfa
NCT05722015
P3Active, not recruitingMetastatic Non-small Cell Lung Cancer3772024-07-12 (-2 mo)
Pembrolizumab 200 mg
NCT03765918
P3Active, not recruitingHead and Neck Neoplasms7142024-07-25 (+18 mo)
ART
NCT05631093
P3Active, not recruitingHIV-1 Infection5532024-10-10
DOR/ISL
NCT05630755
P3Active, not recruitingHIV-1 Infection5142024-10-25 (+1 mo)
Pembrolizumab Formulated with Berahyaluronidase Alfa
NCT06212752
P3Active, not recruitingMetastatic Non-small Cell Lung Cancer392024-11-06 (+1 mo)
Pembrolizumab
NCT05116189
P3Active, not recruitingOvarian Cancer; Carcinoma, Ovarian Epithelial6432025-03-05 (-4 mo)
Pembrolizumab (+) Berahyaluronidase alfa
NCT06099782
P2Active, not recruitingNon-Small Cell Lung Cancer; Renal Cell Carcinoma1472025-04-09 (+1 mo)
Pembrolizumab
NCT03924895
P3Active, not recruitingUrinary Bladder Cancer, Muscle-invasive5952025-06-06 (+4 mo)
Olaparib
NCT03742895
P2Active, not recruitingAdvanced Solid Neoplasms3292025-08-12 (+27 mo)
DOR/ISL
NCT05705349
P3Active, not recruitingHIV-1 Infection5372025-10-13 (+7 mo)
DOR/ISL
NCT05766501
P3Active, not recruitingHIV Infection6412025-10-16 (-3 mo)
KEYNOTE-B15
NCT04700124
P3Active, not recruitingBladder Cancer8082025-10-27 (-2 mo)
Belzutifan
NCT04586231
P3Active, not recruitingCarcinoma, Renal Cell7472026-02-02 (+13 mo)
Pembrolizumab
NCT05899049
P3Active, not recruitingCarcinoma, Renal Cell2512026-02-04 (-16 mo)
Pembrolizumab
NCT04736706
P3Active, not recruitingCarcinoma, Renal Cell16882026-02-04 (-9 mo)
Pembrolizumab (+) Berahyaluronidase alfa
NCT06698042
P3Active, not recruitingLung Cancer; Non-Small Cell Lung Cancer672026-03-12 (-3 mo)
Tulisokibart
NCT06956235
P2Active, not recruitingHidradenitis Suppurativa1492026-04-02 (-7 mo)
Frespaciguat
NCT05612035
P2Active, not recruitingPulmonary Hypertension; Chronic Obstructive Pulmonary Disease1292026-04-09 (+13 mo)
pembrolizumab
NCT04895358
P3Active, not recruitingBreast Neoplasms3422026-04-24 (+24 mo)
IV Tulisokibart
NCT06052059
P3Active, not recruitingUlcerative Colitis11092026-08-12 (-40 mo)
REJOICE-GI01
NCT06864169
P2Active, not recruitingGastrointestinal Cancer1602026-08-18 (+1 mo)
Tulisokibart
NCT07176390
P2Active, not recruitingArthritis, Rheumatoid1852026-09-07 (-6 mo)
TroFuse-015
NCT06356311
P3Active, not recruitingGastroesophageal Cancer4732026-10-19 (-3 mo)
Belzutifan
NCT05239728
P3Active, not recruitingCarcinoma, Renal Cell18002026-10-28 (-12 mo)
Pembrolizumab
NCT04634877
P3Active, not recruitingEndometrial Neoplasms9902026-11-20 (+17 mo)
Belzutifan
NCT05468697
P1/2Active, not recruitingRenal Cell Carcinoma602026-12-22 (-3 mo)
Sacituzumab Govitecan
NCT05609968
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung6142027-01-12
9vHPV Vaccine
NCT04199689
P3Active, not recruitingPapillomavirus Infections60332027-01-15 (+13 mo)
Pembrolizumab
NCT04241185
P3Active, not recruitingUrinary Bladder Neoplasms5202027-01-31 (+4 mo)
pembrolizumab
NCT03407144
P2Active, not recruitingHodgkin Lymphoma3402027-02-12 (+39 mo)
Tulisokibart
NCT07486960
P2Active, not recruitingPsoriatic Arthritis1402027-02-17
Pembrolizumab
NCT04976634
P2Active, not recruitingNeoplasm Malignant7302027-03-22 (+8 mo)
Tulisokibart
NCT07133633
P2Active, not recruitingRadiographic Axial Spondyloarthritis3152027-03-29 (-3 mo)
Posaconazole IV 6 mg/kg
NCT04665037
P2RecruitingInvasive Fungal Infection402027-03-31 (+44 mo)
Pembrolizumab
NCT06305767
P1/2Active, not recruitingBladder Cancer2302027-04-23 (+6 mo)
pembrolizumab
NCT02628067
P2Active, not recruitingAdvanced Cancer; Anal Carcinoma16092027-05-04 (+109 mo)
Pembrolizumab
NCT04380636
P3Active, not recruitingLung Neoplasms; Carcinoma, Non-Small-Cell Lung8702027-05-05 (+10 mo)
Belzutifan
NCT06428396
P2Active, not recruitingMetastatic Breast Cancer1202027-05-05 (-2 mo)
Sacituzumab tirumotecan
NCT06074588
P3Active, not recruitingNon-small Cell Lung Cancer (NSCLC)5562027-05-10
Nemtabrutinib
NCT05624554
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma3002027-05-19 (+3 mo)
pembrolizumab
NCT05173987
P3Active, not recruitingEndometrial Neoplasms2802027-05-27 (+10 mo)
Coformulated favezelimab/pembrolizumab
NCT05845814
P1/2Active, not recruitingMetastatic Urothelial Carcinoma; Urothelial Neoplasms3902027-05-31
MK-6916
NCT07862595
P2RecruitingPain Management3802027-06-10
Paclitaxel
NCT05319730
P1/2RecruitingEsophageal Squamous Cell Carcinoma2302027-06-11 (+25 mo)
I-DXd
NCT07405151
P1/2RecruitingOesophageal Squamous Cell Carcinoma602027-06-12
Suvorexant
NCT06655883
P3RecruitingInsomnia3002027-06-24 (+10 mo)
Sacituzumab tirumotecan
NCT06312176
P3RecruitingBreast Neoplasms12002027-07-11
Bomedemstat
NCT06079879
P3Active, not recruitingEssential Thrombocythemia3402027-07-14 (-13 mo)
MK-8527
NCT07044297
P3Active, not recruitingHuman Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis43902027-07-22 (-3 mo)
MK-3120
NCT07222488
P1/2RecruitingBladder Cancer; Urinary Bladder Neoplasms452027-07-30 (-19 mo)
ISL
NCT06891066
P2Active, not recruitingHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1502027-08-10 (-2 mo)
Zilovertamab vedotin
NCT05139017
P2/3RecruitingDLBCL; Diffuse Large B-Cell Lymphoma2902027-09-24 (+33 mo)
Bomedemstat
NCT06456346
P3Active, not recruitingEssential Thrombocythemia3002027-09-28 (-20 mo)
MK-7262
NCT07614984
P2RecruitingLipoprotein(a)7502027-10-12
MK-8527
NCT07071623
P3RecruitingHuman Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis45802027-10-18 (-3 mo)
MK-8690
NCT07895524
P2Not yet recruitingRheumatoid Arthritis602027-10-19
Pembrolizumab 200 mg
NCT02861573
P1/2Active, not recruitingMetastatic Castration-Resistant Prostate Cancer12002027-10-22 (+92 mo)
Pembrolizumab 200 mg
NCT04624204
P3Active, not recruitingSmall Cell Lung Cancer6722027-10-28
MK-8690
NCT07463183
P2RecruitingColitis Ulcerative; Ulcerative Colitis1002027-10-28
Opevesostat
NCT06979596
P2RecruitingMalignant Neoplasm2502027-11-04 (-32 mo)
Enlicitide Decanoate
NCT07821944
P3RecruitingHyperlipidemia; Hypercholesterolemia1502027-11-26
EXPrESSIVE-18
NCT07850609
P2RecruitingHIV802027-12-02
Zilovertamab vedotin
NCT06890884
P2RecruitingLymphoma, Large B-Cell, Diffuse5942027-12-13
V503
NCT07785843
P3RecruitingPapillomavirus Infections9302027-12-18
INTerpath-004
NCT06307431
P2Active, not recruitingRenal Cell Carcinoma2722028-01-08
TroFuse-005
NCT06132958
P3Active, not recruitingEndometrial Cancer7102028-01-10
Calderasib
NCT06345729
P3RecruitingNon-small Cell Lung Cancer3482028-01-24 (-13 mo)
TroFuse-007
NCT06170788
P3RecruitingNon-small Cell Lung Cancer (NSCLC)6142028-01-25
Pembrolizumab
NCT02332668
P1/2RecruitingMelanoma; Lymphoma3702028-02-02
MK-3120
NCT06818643
P1/2RecruitingAdvanced Solid Tumors; Malignant Neoplasm2702028-02-08
Sacituzumab tirumotecan
NCT06483334
P1/2Active, not recruitingMetastatic Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma382028-03-31 (-4 mo)
Pembrolizumab (+) Berahyaluronidase alfa
NCT06041802
P2Active, not recruitingSquamous Cell Carcinoma192028-03-31 (+13 mo)
V503
NCT03998254
P3Active, not recruitingPapillomavirus Infections60002028-03-31 (+14 mo)
Ramucirumab
NCT06445972
P1/2RecruitingGastroesophageal Junction; Gastroesophageal Adenocarcinoma2102028-05-09 (+16 mo)
Opevesostat
NCT06136650
P3RecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms13142028-05-10 (-31 mo)
Sacituzumab Tirumotecan
NCT06459180
P3Active, not recruitingCervical Cancer6862028-06-15 (-4 mo)
LIGHTRAY EXT
NCT06925750
P2Active, not recruitingPulmonary Arterial Hypertension1302028-06-16 (+9 mo)
Ifinatamab deruxtecan
NCT06925737
P3RecruitingProstate Cancer; Prostatic Neoplasms14402028-06-26
Intismeran autogene
NCT06961006
P2Active, not recruitingMalignant Melanoma1602028-07-22
Pembrolizumab
NCT03711032
P3Active, not recruitingHigh-risk Non-muscle Invasive Bladder Cancer13972028-07-31 (+74 mo)
Sacituzumab tirumotecan
NCT06305754
P3Active, not recruitingNon-small Cell Lung Cancer (NSCLC)5502028-08-17
Pembrolizumab
NCT05239741
P3Active, not recruitingColorectal Neoplasms1002028-09-19 (+22 mo)
MOONBEAM
NCT05587712
P2RecruitingPulmonary Arterial Hypertension422028-09-21
MK-2010
NCT07793942
P2RecruitingMalignant Neoplam; Advanced Solid Tumors4802028-09-26
Enlicitide Decanoate
NCT06492291
P3Active, not recruitingHypercholesterolemia30002028-10-13
IV Tulisokibart
NCT06430801
P3RecruitingCrohn's Disease12002028-10-30 (-10 mo)
MK-8748
NCT07705555
P3RecruitingDiabetic Retinopathy; Macular Edema9602028-10-31
Pembrolizumab (+) Berahyaluronidase alfa
NCT06504394
P2Active, not recruitingClassical Hodgkin Lymphoma Recurrent; Classical Hodgkin Lymphoma Refractory662028-11-08
Doravirine
NCT04375800
P2RecruitingHuman Immunodeficiency Virus (HIV) Infection842028-11-12 (+43 mo)
OMAHA-003
NCT06136624
P3RecruitingProstate Cancer Metastatic13102028-11-30 (+5 mo)
MK-8748
NCT07705607
P3RecruitingDiabetic Retinopathy; Macular Edema11042028-11-30
Patritumab deruxtecan
NCT06596694
P1/2Active, not recruitingGastrointestinal Cancer1802028-12-07 (+4 mo)
SOTERIA
NCT07218029
P3Active, not recruitingPulmonary Arterial Hypertension8152028-12-07
Nemtabrutinib
NCT04728893
P2RecruitingHematologic Malignancies; Waldenstroms Macroglobulinaemia4902029-01-04 (+18 mo)
Pembrolizumab
NCT06422143
P3RecruitingNon-small Cell Lung Cancer; NSCLC8512029-01-12
Opevesostat
NCT06353386
P1/2Active, not recruitingProstatic Neoplasms, Castration-Resistant2202029-01-15 (+10 mo)
ISL
NCT07266831
P2/3RecruitingHuman Immunodeficiency Virus Type 1 (HIV-1) Infection5702029-02-01
Gocatamig
NCT06780137
P1/2RecruitingSmall Cell Lung Cancer3272029-02-15 (+6 mo)
9vHPV vaccine
NCT05314023
P3Active, not recruitingGenital Warts15902029-02-19
Zilovertamab vedotin
NCT05562830
P1/2Active, not recruitingUrothelial Carcinoma482029-02-26 (+16 mo)
Raludotatug Deruxtecan
NCT06843447
P1/2RecruitingOvarian Cancer Recurrent6052029-03-27
Calderasib
NCT06997497
P3RecruitingColon Adenocarcinoma; Rectal Adenocarcinoma4772029-03-28 (-5 mo)
Pembrolizumab
NCT07302347
P1/2RecruitingMalignant Neoplasm; Carcinoma, Merkel Cell202029-03-30
Zilovertamab vedotin
NCT06395103
P1/2RecruitingB-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma902029-03-31
MK-2750
NCT07876128
P1/2Not yet recruitingAdvanced Solid Tumors; Malignant Neoplasm3002029-04-12
waveLINE-007
NCT05406401
P2Active, not recruitingLymphoma, Large B-Cell, Diffuse (DLBCL)602029-04-26
Sacituzumab tirumotecan
NCT06824467
P3RecruitingOvarian Cancer; Fallopian Tube Cancer7702029-04-27 (-11 mo)
ENHANCE-3
NCT07874815
P3RecruitingPulmonary Disease, Chronic Obstructive21362029-04-29
MK-2214
NCT07033494
P2RecruitingEarly Alzheimer's Disease3402029-04-30 (-4 mo)
Zilovertamab vedotin
NCT05458297
P2Active, not recruitingChronic Lymphocytic Leukemia; Mantle Cell Lymphoma1892029-05-17 (+26 mo)
Sotatercept
NCT07646860
P2RecruitingPulmonary Arterial Hypertension62029-05-24
9vHPV Vaccine
NCT05285826
P3Active, not recruitingPapillomavirus Infections81002029-05-25 (+54 mo)
MK-8591A
NCT04776252
P3Active, not recruitingHIV-1 Infection20002029-05-29 (+38 mo)
Tulisokibart
NCT07861074
P2RecruitingNoninfectious Intermediate, Posterior, or Panuveitis872029-06-05
INTerpath-13
NCT07221474
P2RecruitingSquamous Non-small Cell Lung Cancer1802029-07-02
Zilovertamab vedotin
NCT06717347
P3RecruitingDiffuse Large B-Cell Lymphoma10462029-07-02 (-33 mo)
TroFuse-031
NCT07419295
P3RecruitingBladder Cancer5902029-07-27
9vHPV vaccine
NCT05450705
P3Active, not recruitingPapillomavirus Infections15002029-08-03
MK-1084
NCT07286149
P1/2RecruitingLung Neoplasm Malignant1402029-08-17
Vericiguat tablet
NCT05714085
P2/3RecruitingHeart Failure; Left Ventricular Systolic Dysfunction3422029-08-20 (-8 mo)
Pembrolizumab
NCT06469944
P1/2RecruitingGastroesophageal Junction; Gastroesophageal Adenocarcinoma1602029-09-12 (+32 mo)
DOR/ISL
NCT07862569
P2Not yet recruitingHIV-1; HIV Infection452029-09-24
Tulisokibart
NCT07867938
P2RecruitingPulmonary Sarcoidosis1582029-10-05
Sacituzumab tirumotecan
NCT06428409
P1/2RecruitingColorectal Cancer; Pancreatic Ductal Adenocarcinoma2202029-10-16 (+10 mo)
9vHPV vaccine
NCT04708041
P3Active, not recruitingPapillomavirus Infections7002029-10-23 (+4 mo)
Intismeran autogene
NCT05933577
P3Active, not recruitingMelanoma10892029-10-26
MK-1084
NCT07252739
P2RecruitingMalignant Neoplasm1402029-11-15
Enlicitide Decanoate
NCT06008756
P3Active, not recruitingArteriosclerosis; Hypercholesterolaemia145502029-11-29
Calderasib
NCT07190248
P3RecruitingNon-small Cell Lung Cancer6752029-12-07
coformulation pembrolizumab/quavonlimab
NCT04938817
P1/2Active, not recruitingSmall Cell Lung Carcinoma1102029-12-10 (+37 mo)
Patritumab deruxtecan
NCT06797635
P2RecruitingBreast Neoplasms; Breast Cancer3722029-12-31
CHORUS
NCT07839585
P3Not yet recruitingPulmonary Hypertension3522030-01-08
Miransertib
NCT04980872
P2Active, not recruitingPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)602030-02-07 (+53 mo)
Sacituzumab tirumotecan
NCT06841354
P3RecruitingTriple Negative Breast Neoplasms10002030-05-18
INTerpath-002
NCT06077760
P3Active, not recruitingNon-small Cell Lung Cancer8682030-06-25
WaveSpan-008
NCT07519772
P1/2RecruitingLymphoma, Non-Hodgkin; Lymphoma, Follicular2802030-07-01
Belzutifan
NCT07489495
P3RecruitingCarcinoma, Renal Cell7582030-11-27
Gocatamig
NCT07227597
P1/2RecruitingSmall Cell Lung Cancer Extensive Stage1702030-11-29
Pembrolizumab
NCT06393374
P3RecruitingTriple-Negative Breast Cancer15302030-12-16
Patritumab Deruxtecan
NCT06941272
P1/2RecruitingMalignant Neoplasm502030-12-30
Pembrolizumab (K)
NCT03725059
P3Active, not recruitingBreast Cancer12402031-01-24
MOVe-NOW
NCT06667700
P3RecruitingCoronavirus Disease (COVID-19)30822031-01-26
MK-3120
NCT07232602
P1/2RecruitingBladder Cancer552031-07-08 (+9 mo)
Ifinatamab Deruxtecan
NCT07630974
P1/2RecruitingMalignant Neoplasm1342031-08-17
R-DXd
NCT07743164
P3RecruitingOvarian Cancer; Peritoneal Cancer6462031-08-31
Intismeran autogene
NCT06833073
P2RecruitingUrinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms3082031-09-03
V181
NCT07013487
P3Active, not recruitingHealthy120002031-09-06 (-5 mo)
MK-2010
NCT07785609
P2RecruitingAdvanced Solid Tumors; Malignant Neoplasm2002031-09-30
Docetaxel
NCT06863272
P1/2RecruitingCastration-Resistant Prostatic Cancer; Metastasis3602031-10-01 (+19 mo)
Belzutifan
NCT07049926
P1/2RecruitingRenal Cell Carcinoma1402031-10-26
Pembrolizumab
NCT07216703
P3RecruitingCervical Cancer10232031-10-29
TroFuse-055
NCT07829783
P3RecruitingBladder Cancer4002031-11-17
Gocatamig
NCT07908537
P3Not yet recruitingSmall Cell Lung Cancer5642031-12-08
Pembrolizumab
NCT06780111
P1/2RecruitingEsophageal Squamous Cell Carcinoma2982032-01-04 (+10 mo)
Pembrolizumab (neoadjuvant)
NCT06788912
P2Active, not recruitingLung Neoplasm Malignant602032-02-06 (+3 mo)
Pembrolizumab
NCT04165070
P1/2RecruitingCarcinoma, Non-Small-Cell Lung4502032-02-13
LITESPARK-033
NCT07227402
P3RecruitingRenal Cell Carcinoma9042032-02-27
R-DXD
NCT06780098
P2RecruitingLung Neoplasm1442032-03-02 (+18 mo)
Pembrolizumab
NCT06731907
P2RecruitingNon-small Cell Lung Cancer902032-03-12
Raludotatug Deruxtecan
NCT06780085
P2Active, not recruitingCarcinoma, Non-Small-Cell Lung962032-03-12 (+18 mo)
R-DXd
NCT07776691
P3RecruitingOvarian Cancer; Ovarian Neoplasms8022032-03-19
KANDLELIT-014
NCT07209111
P2RecruitingNeoplasm Malignant1502032-04-09
TroFuse-033
NCT06952504
P3RecruitingEndometrial Cancer11232032-05-24
Nemtabrutinib
NCT05947851
P3RecruitingLeukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic7352032-06-01 (-13 mo)
Bomedemstat
NCT07722611
P2/3RecruitingPolycythemia Vera3802032-06-25
TroFuse-01A
NCT07908524
P1/2Not yet recruitingMetastatic Castration-resistant Prostate Cancer2902032-06-29
MK-1045
NCT07634471
P2/3RecruitingFollicular Lymphoma9602032-07-23
Patritumab deruxtecan
NCT06686394
P1/2RecruitingBreast Neoplasms; Breast Cancer1812032-08-02 (+37 mo)
Nemtabrutinib
NCT06136559
P3RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma12002032-09-07
Belzutifan
NCT04924075
P2RecruitingPheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor3552032-11-18 (+92 mo)
Calderasib
NCT07554339
P3RecruitingNon-small Cell Lung Cancer3102032-12-15
TroFuse-021
NCT07318558
P3RecruitingOvarian Neoplasms; Ovarian Cancer9002033-02-25
Sacituzumab tirumotecan
NCT06966700
P3RecruitingBreast Neoplasms; Triple Negative Breast Neoplasms24002033-03-23
Pembrolizumab
NCT06623422
P3RecruitingCarcinoma, Non-Small-Cell Lung6802033-05-16
Patritumab deruxtecan
NCT07060807
P3RecruitingBreast Neoplasms10002033-07-14
MK-1045
NCT07570173
P2/3RecruitingB-cell Acute Lymphoblastic Leukemia3402033-10-18
MK-1045
NCT07709000
P2RecruitingChronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma602033-11-16
Enlicitide Decanoate
NCT07058077
P2/3RecruitingHeterozygous Familial Hypercholesterolemia (HeFH)1532033-12-04
Belzutifan
NCT07700758
P2RecruitingMalignant Neoplasm152034-01-02
TroFuse-019
NCT06312137
P3RecruitingNon Small Cell Lung Cancer7802034-02-21
Belzutifan
NCT07405164
P3RecruitingVon Hippel-Lindau Disease; Malignant Neoplasms4502034-04-22
INTerpath-014
NCT07513376
P3RecruitingNon-small Cell Lung Cancer8762034-08-22
Bomedemstat
NCT06351631
P3RecruitingThrombocythemia, Essential; Primary Myelofibrosis4002034-12-04
HARMONIZE
NCT06814145
P2Active, not recruitingHypertension, Pulmonary4402035-08-10 (+76 mo)
WaveSpan-010
NCT07917754
P2/3Not yet recruitingLymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma4702037-03-13
Tulisokibart
NCT06651281
P3RecruitingCrohn Disease; Colitis, Ulcerative13802037-12-17
KANDLELIT-013
NCT07431827
P3RecruitingNon-small Cell Lung Cancer4002039-10-26
Pembrolizumab
NCT03486873
P3RecruitingSolid Tumors; Hematologic Malignancies35002043-08-04